The Peripheral Neuropathic Pain market report also offers comprehensive insights into the Peripheral Neuropathic Pain market size, share, Peripheral Neuropathic Pain epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Peripheral Neuropathic Pain market size growth forward.
Some of the key highlights from the Peripheral Neuropathic Pain Market Insights Report:
-
Several key pharmaceutical companies, including Daiichi Sankyo, Scilex Pharmaceuticals, Azurity Pharmaceuticals, Lexicon Pharmaceuticals, Merz Therapeutics, Apurano Pharmaceuticals, Vertex Pharmaceuticals, WEX Pharmaceuticals, Scilex Holding Company, and others, are developing novel products to improve the Peripheral Neuropathic Pain treatment outlook.
-
In November 2023, Lexicon Pharmaceuticals announced the enrollment of the first patient in the PROGRESS study, a Phase IIb, dose-ranging, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial with an open-label extension, evaluating LX9211 for diabetic peripheral neuropathic pain.
-
In 2023, the Peripheral Neuropathic Pain (PNP) market in the 7MM was valued at approximately USD 12 billion, with projections indicating significant growth by 2034 at a notable CAGR. The United States holds the largest market share compared to EU4 (Germany, Spain, Italy, France), the UK, and Japan.
-
PNP arises from damage to the peripheral nervous system due to factors such as mechanical trauma, metabolic disorders, infections, neurotoxic chemicals, or tumors. Among its various causes, diabetic peripheral neuropathy (DPN) is the most common subtype in the 7MM, followed by lumbosacral radiculopathy (LSR), post-operative and post-traumatic PNP, and chemotherapy-induced peripheral neuropathy (CIPN). Postherpetic neuralgia (PHN), a complication of shingles, is the least prevalent.
-
Treatment options include anticonvulsants, tricyclic antidepressants, and SNRIs, alongside topical agents like capsaicin and lidocaine. Nonpharmacological approaches, such as physical therapy and TENS, complement drug therapies. Approved treatments include QUTENZA, NUCYNTA ER, HORIZANT, ZTlido, and TARLIGE.
-
The market is expected to expand significantly with the introduction of emerging therapies, offering novel treatment options. Key pipeline drugs include AP-325, XEOMIN, VX-548, LX9211, HALNEURON, SEMDEXA, and adezunap. Among these, LX9211 and SEMDEXA are projected to lead the market by 2034. However, adezunap faces challenges such as legal restrictions, public stigma, and quality control concerns, limiting its adoption. Meanwhile, ZTlido has captured a substantial share of the lidocaine patch market but may encounter competition from generic alternatives.
-
The market’s growth will primarily be driven by the development of more targeted and personalized therapies addressing both symptoms and underlying causes of PNP.
-
As per DelveInsight analysis, the Peripheral Neuropathic Pain market is anticipated to witness growth at a considerable CAGR
Strategise your business goals by understanding market dynamics @ Peripheral Neuropathic Pain Market Landscape
Peripheral Neuropathic Pain Overview
Peripheral neuropathies refer to disorders affecting peripheral nerve cells and fibers, arising from various underlying conditions. These nerves include cranial nerves, spinal nerve roots and ganglia, nerve trunks and branches, as well as autonomic nervous system nerves. Peripheral neuropathies are classified into different types, such as mononeuropathies (affecting a single nerve), multiple mononeuropathies or mononeuropathy multiplex (impacting two or more nerves in separate areas), and polyneuropathies (involving widespread nerve damage).
The diverse symptom presentation allows for the identification of distinct clinical phenotypes, which are crucial for guiding diagnostic evaluations. Nerve conduction studies help determine whether the neuropathy is axonal or demyelinating and assess its severity. Additional diagnostic methods, such as genetic testing, cerebrospinal fluid (CSF) analysis, nerve imaging, and nerve biopsy, may be utilized in specific cases to refine diagnosis and treatment approaches.
Do you know the treatment paradigms for different countries? Download our Peripheral Neuropathic Pain Market Sample Report
Peripheral Neuropathic Pain Epidemiology Insights
-
In 2023, the United States reported the highest number of Peripheral Neuropathic Pain (PNP) cases among the 7MM, totaling approximately 35.2 million.
-
Across the 7MM, the highest incidence of severe cases was observed in post-operative and post-traumatic PNP, whereas moderate cases were more prevalent in postherpetic neuralgia (PHN).
Peripheral Neuropathic Pain Epidemiology Segmentation
DelveInsight’s Peripheral Neuropathic Pain market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Peripheral Neuropathic Pain historical patient pools and forecasted Peripheral Neuropathic Pain patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Peripheral Neuropathic Pain Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:
-
Peripheral Neuropathic Pain Prevalence
-
Age-Specific Peripheral Neuropathic Pain Prevalence
-
Gender-Specific Peripheral Neuropathic Pain Prevalence
-
Diagnosed and Treatable Cases of Peripheral Neuropathic Pain
Visit for more @ Peripheral Neuropathic Pain Epidemiological Insights
Peripheral Neuropathic Pain Market Outlook
Pharmaceutical companies such as Scilex Holding Company, Grünenthal and Averitas Pharma, Eli Lilly and Company, Mitsubishi Tanabe Pharma Corporation, AstraZeneca, Asahi Kasei Pharma, and Veloxis Pharmaceuticals are actively advancing their lead candidates through various stages of clinical development to explore potential treatments for Peripheral Neuropathic Pain (PNP).
Among emerging therapies, LX9211 and SEMDEXA are anticipated to become market leaders, significantly shaping the PNP market across the 7MM by 2034.
In 2023, opioids dominated the U.S. PNP market, generating approximately USD 2,400 million in revenue, followed closely by NSAIDs at around USD 2,300 million.
Adezunap is expected to see limited adoption in the 7MM due to regulatory challenges, public perception issues, high-risk classification, and quality control concerns related to cannabidiol in emerging markets, all of which impact its market acceptance and manufacturing standards.
Within the EU4 and the UK, NSAIDs contributed the highest revenue in the PNP market, generating approximately USD 600 million in 2023.
Peripheral Neuropathic Pain Marketed Drugs
-
QUTENZA (capsaicin): Grünenthal and Averitas Pharma
-
ZTLIDO (lidocaine): Scilex Pharmaceuticals
Peripheral Neuropathic Pain Emerging Drugs
-
SEMDEXA (SP-102): Scilex Holding Company
-
Adezunap (AP707): Apurano Pharmaceuticals
Peripheral Neuropathic Pain Key Companies
-
Daiichi Sankyo, Scilex Pharmaceuticals, Azurity Pharmaceuticals, Lexicon Pharmaceuticals, Merz Therapeutics, Apurano Pharmaceuticals, Vertex Pharmaceuticals, WEX Pharmaceuticals, Scilex Holding Company, and others
For more information, visit Peripheral Neuropathic Pain Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Peripheral Neuropathic Pain Market Report:
-
11 Years Forecast
-
7MM Coverage
-
Descriptive overview of Peripheral Neuropathic Pain, causes, signs and symptoms, diagnosis, treatment
-
Comprehensive insight into Peripheral Neuropathic Pain epidemiology in the 7MM
-
Peripheral Neuropathic Pain marketed and emerging therapies
-
Peripheral Neuropathic Pain companies
-
Peripheral Neuropathic Pain market drivers and barriers
Table of Contents:
1 Peripheral Neuropathic Pain Market Key Comprehensive Insights
2 Peripheral Neuropathic Pain Market Report Introduction
3 Competitive Intelligence Analysis for Peripheral Neuropathic Pain
4 Peripheral Neuropathic Pain Market Analysis Overview at a Glance
5 Executive Summary of Peripheral Neuropathic Pain
6 Peripheral Neuropathic Pain Epidemiology and Market Methodology
7 Peripheral Neuropathic Pain Epidemiology and Patient Population
8 Peripheral Neuropathic Pain Patient Journey
9 Peripheral Neuropathic Pain Treatment Algorithm, Peripheral Neuropathic Pain Current Treatment, and Medical Practices
10 Key Endpoints in Peripheral Neuropathic Pain Clinical Trials
11 Peripheral Neuropathic Pain Marketed Therapies
12 Peripheral Neuropathic Pain Emerging Therapies
13 Peripheral Neuropathic Pain: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Peripheral Neuropathic Pain
16 Peripheral Neuropathic Pain Market Key Opinion Leaders Reviews
18 Peripheral Neuropathic Pain Market Drivers
19 Peripheral Neuropathic Pain Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Peripheral Neuropathic Pain Epidemiology 2034
DelveInsight’s “Peripheral Neuropathic Pain – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Peripheral Neuropathic Pain epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Peripheral Neuropathic Pain Pipeline 2024
“Peripheral Neuropathic Pain Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Peripheral Neuropathic Pain market. A detailed picture of the Peripheral Neuropathic Pain pipeline landscape is provided, which includes the disease overview and Peripheral Neuropathic Pain treatment guidelines.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/